The effects of therapeutic doses of theophylline, another commonly prescribed bronchodilator, on resting energy expenditure have not been studied in adult humans. We therefore studied the effects of theophylline on resting Vo2 and Vco2 in normal volunteers. The response to a superimposed acute inhalation of salbutamol was also tested.
There is evidence that resting oxygen consumption in normally nourished patients with chronic airflow limitation is raised by about 10% above normal.1 This increase may be attributed to the features of the disease, including an increase in respiratory muscle work, the bronchodilator treatment, or a combination of the two.
A recent study on normal volunteers in our laboratory has shown that oxygen consumption (Vo2) and carbon dioxide production (Vco2) are increased by acute therapeutic doses of inhaled salbutamol.2 This acute metabolic effect of salbutamol was, however, abolished by regular administration,3 suggesting that chronic salbutamol treatment may not contribute to the increased Vo2 and Vco2 observed in patients with chronic airflow limitation.
The effects of therapeutic doses of theophylline, another commonly prescribed bronchodilator, on resting energy expenditure have not been studied in adult humans. We therefore studied the effects of theophylline on resting Vo2 and Vco2 in normal volunteers. The response to a superimposed acute inhalation of salbutamol was also tested.
Methods
Ten healthy, non-smoking volunteers (six men, aged 21-48 years and weighing 50-85 kg) were studied. The body mass index ranged between 18-2 and 32-2 and these two extreme values were observed in two of the female subjects; in the remaining eight subjects body mass index was between 21-5 and 26&7. Each volunteer was fasted for at least eight hours before each test and abstained from caffeine and chocolate throughout the study. Prior to the study all subjects were regular but moderate coffee and tea drinkers (2-5 cups per day). Informed consent and local ethics committee approval was obtained.
Oxygen consumption (Vo2) and carbon dioxide production (Vco2) were measured by indirect calorimetry using an open canopy technique with a mass spectrometer, described in detail elsewhere. 2 Briefly, a plastic hood was placed over the subject's head providing a constant flow of air by a fan distal to a mixing box at a flow rate of 95-110 1/min. The apparatus was calibrated daily at two points using 100% nitrogen and a precisely known gas mixture (argon 2-12%, oxygen 15-45%, carbon dioxide 1 05%, and nitrogen 81 38%). Throughout the study room temperature ranged between 17 9°C and 24°C (median 20 3°C), barometric pressure between 749 and 775 mm Hg (median 763 mm Hg), and ambient humidity between 23% and 54% (median 36 5%) All measurements were made at toom temperature and pressure. Corrections of gas volumes to standard temperature and barometric pressure dry were not carried out because the maximum changes obtained with the corrections were well below the 3% resolution of the method to determine Vo2 and Vco2. 1) . Following the initial control measurements subjects were knowingly given theophylline before each test period for three reasons: firstly, to allow acclimatisation to the side effects of theophylline; secondly, to establish the dose of theophylline required in each subject to achieve therapeutic plasma levels; and thirdly, to blunt the ability of subjects to distinguish placebo from drug, a method successfully used in previous volunteer studies using theophylline. [5] [6] [7] [8] [9] [10] days was then intercalated, followed by a further four days of "known" theophylline at the same dose as that which had previously produced therapeutic levels, after which tablet B (theophylline or placebo 1, depending on what A had been) was given for four days. This second four-day "known" theophylline period was shorter because the appropriate individual dose to achieve therapeutic levels had been determined in the first seven day period. There was then another tablet-free period of 10-20 days after which tablet C, which was always placebo (placebo 2) was taken for four days. The minimum duration of this second tabletfree period was made twice as long as the first because of our early suspicion that there might be a residual effect of theophylline four days after discontinuation.
There were thus two independent four-day placebo periods, one "double blind" period (placebo 1) and a second "single blind" period (placebo 2) at the end of each study. For the purpose of numbering the days of the experiments the first (5-10 days) and the second (10-20 days) tablet-free periods are standardised to 5 and 10 days respectively for all subjects (fig 1) .
Test tablets were stopped after the evening dose in the day preceding, and at least 10 hours before, any Vo2/Vco2 measurement. The random allocation of theophylline and placebo 1 to tablets A and B was made in the hospital pharmacy and the code was only broken at the end of each study. Both subjects and experimenters were blinded to the nature of all tablets except tablet C which only two experimenters knew to be always placebo. Figure  1 depicts the sequence of tests and interventions.
Vo2, Vco2, and heart rate (obtained from a "Datascope" ECG monitor connected to shoulder and precordial electrodes) were always measured first thing in the morning, between 08.00 and 09.00 hours, 10-12 hours after the last dosing. In addition to the control measurements taken before and on day 0, a further five measurements were taken at the end of each tablet period on days 7, 11, 20, 24, and 38. On days 0, 11, 24, and 38 each set of measurements started by recording baseline Vo2 and Vco2 values and then recording Vo2 and Vco2 at 5, 15, 30, and 60 minutes after the inhalation of 800 tg salbutamol (eight puffs, through a spacing device). The number and the timing of the post-inhalation data points were chosen based on our previous experience of the minimum points necessary to accurately define an acute response to salbutamol. Venous blood samples for measurement of trough serum theophylline levels were obtained in the morning of day 4 and of days 11, 20, 24, and 38, at the end of each period taking tablets A, B and C. Side effects to both theophylline and salbutamol were noted at the time of indirect calorimetry.
ANALYSIS OF DATA
All subjects acted as their own controls. Vo2 and Vco2 are expressed as mean (SE) values in ml/min/kg and comparisons made using Student's paired t test since previous similar data appeared normally distributed.2 Respiratory ex- Table 1 Mean (SE) resting baseline oxygen consumption (Vo), carbon dioxide production (Vco) in ml/kglmin, respiratory exchange ratio (R), and heart rate (HR, beatslmin) in 10 subjects taken before the test (control), at the end of 11 days of treatment with theophylline (T), and at the end of two four-day placebo periods (Pl and P2). Paired comparisons between the various groups were made using the Student's paired t test. tained in control measurements and those obtained at the end of each tablet period and between theophylline and placebo 1 periods.
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Results
The range of theophylline dosage required to attain sustained therapeutic levels in all subjects was 400-800 mg/day. At the time of Vo2 measurements all subjects had serum trough levels within the range 8-4-13-5 mg/l.
BASELINE MEASUREMENTS
There were significant increases in mean resting Vo2 during theophylline administration, by 6-5% when compared with placebo 1 and by 9% when compared with control. The mean IO Vco2 during theophylline administration was hylline also 5% higher than placebo 1 and 6% higher than control, but these values did not reach significance at the 5% level. Table 2 Mean (SE) values for the differences between baseline measurements of oxygen consumption (Vo), carbon dioxide production ((Vco), and heart rate (HR), and measurements taken over one hour after inhalation of 800 Lg salbutamol at the end of each of three test periods: control (C), placebo (P), and theophyUline (T). The baseline values obtained before the inhalations were subtracted from each value obtained at 5, 15, 30, and 60 minutes. These differences from baseline were integrated over the 60 minute period following inhalation and expressed in ml/kglmin for Vo2/Vco2, and in beatslmin for HR. Thus, only the departures from the baseline values are compared between the control, placebo, and theophylline groups. Vo Vco2 HR Theophylline caused gastrointestinal side effects in most subjects, including mild abdominal discomfort, nausea and diarrhoea, as well as palpitations and insomnia. These effects did not correlate with the serum levels of theophylline and resolved after 2-3 days of theophylline "known" administration in all subjects before starting tablets A or B. Salbutamol produced palpitations and a slight perceived tremor in two of the subjects for the first five minutes following inhalation during the theophylline treatment period only.
Discussion
The increase in Vo2 associated with theophylline administration in this study may contribute to the previously reported approximately 10% increase noted in patients with chronic airflow limitation. ' The longest period of continuous theophylline treatment was 11 days (see fig 1) and it was clear that the thermogenic effects of theophylline were present on days 7 and 20 of "known" theophylline and were maintained on days 11 and 24, suggesting that the effect is established by the fourth day without changing up to 11 days of administration. We did not see evidence of accommodation of the response within the period of time tested. Since we did not obtain daily calorimetry measurements during the onset of theophylline treatment we could not define precisely the point at which the effect was established and whether there might be some accommodation within the first four days of treatment. These findings, however, contrast with our previous, similar study on regular salbutamol treatment which showed a clear accommodation ofthe response to acute inhalation and a lack ofa sustained thermogenic effect after 10 days of regular administration.3 Our results do not however rule out a downregulation of the thermogenic effect of theophylline over the first four days of treatment or over a longer period of time (>11 days).
Our present study did not address the question as to whether background theophylline treatment might prevent the downregulation of the thermogenic response to chronic salbutamol administration observed in our earlier study,' but it was interesting that the acute inhalation of salbutamol, superimposed on the theophylline background, had a merely additive effect on Vo2, Vco2, and heart rate. A potentiation of the effects of salbumatol by theophylline might be expected in this experiment if theophylline exerted its action by inhibition of intracellular phosphodiesterase activity, thus modulating the fi effect of salbutamol in a multiplicative way. There is evidence, however, that plasma therapeutic concentrations of theophylline are not sufficient to produce tissue concentrations of the order required to inhibit phosphodiesterases;5 antagonism of adenosine, which mediates at least part of the cardiac effects of theophylline,' is a more likely mechanism for the observed effects in our experiment. Inhibition of extraneuronal inactivation of the catecholamines may also have played a part in the thermogenic effect of theophylline.6 In this context it is worth noting that previous authors have reported doubling of the thermogenic effects of ephedrine by methylxanthines7 in normal adults and long term maintenance of the thermogenic efficacy of caffeine/ephedrine mixtures. 8 It is of interest to note that there might have been a placebo effect in the heart rate response to salbutamol because it was significantly potentiated during both test periods (theophylline and placebo 1) compared with the control response. We cannot offer a plausible explanation for this apparent dissociation between thermogenic and The cause of the sustained increased whole body oxygen consumption with theophylline observed in this study is unclear. The associated increase in heart rate may have been either an effect of, or a contributing factor to, this increased metabolic rate. Our subjects were always studied under resting conditions so it is unlikely that increased physical activity was a factor underlying the increased oxygen consumption during theophylline treatment. In two of our subjects, however, muscle tremor might have contributed to the increase in Vo2 and Vco2 after salbutamol, but we believe that this had a negligible effect on the overall result since it was observed for the first five minutes after inhalation only during the theophylline treatment. The metabolic effects of theophylline were quite clear in our study, despite all our subjects being regular (but moderate) caffeine users. The body mass index of eight of our 10 subjects was within very narrow limits (21 5-26-7) except for two female subjects where the body mass index was 18-2 and 32-2; we have taken the precaution of repeating the comparisons of tables 1 and 2 having removed the values of these two subjects but this did not alter the mean values or change the significance of any of the results.
In premature infants aminophylline has been shown to increase oxygen consumption by about 20% and this was accompanied by increases in minute ventilation and in the central responsiveness to carbon dioxide9; although not supported by evidence, the authors attributed this metabolic increase to parallel increases in heart rate and in central nervous system activity. Studies in adult rats have also shown a sustained increase in metabolic rate of approximately 20% with aminophylline, but this was almost certainly due to an increase in physical activity associated with the treatment.'0 In adult humans 100 mg oforal caffeine has been shown to cause an increase in resting metabolic rate" of about 4% above control.
None of the human studies, however, offers evidence as to the cause of the increased metabolism associated with treatment with methylxanthines.
In conclusion, theophylline may significantly contribute to the observed increase in Vo2 and Vco2 in patients with chronic airflow limitation.
